Halozyme Therapeutics, Inc. (HALO) News
Follow Halozyme Therapeutics, Inc. (HALO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 31 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Halozyme Reports Q3 Revenue Growth and Raises 2026 Guidance
Halozyme reported Q3 2026 revenue of $493 million, up 39.2% year over year, including royalty revenue of $341 million, up 44%. It raised full-year revenue guidance to $1.86 billion–$1.93 billion and non-GAAP diluted EPS
EQUITY | Nov 05, 2026, 11:04 PM UTC
M
Halozyme Q3 Revenue Jumps 39% on ENHANZE Royalties, Lifts 2026 Outlook
Halozyme Therapeutics reported a 39% increase in third-quarter revenue, driven by ENHANZE royalty growth, and lifted its 2026 outlook.
EQUITY | Nov 05, 2026, 09:48 PM UTC
M
Halozyme Therapeutics Q3 2026 Earnings Call Begins
Halozyme Therapeutics' Q3 2026 earnings call has begun.
EQUITY | Nov 05, 2026, 09:27 PM UTC
M
Halozyme Reports Q3 Results and Raises 2026 Guidance
Total revenue rose 39% year over year, while royalty revenue increased 44%. Halozyme raised its 2026 total revenue and royalty revenue guidance ranges.
EQUITY | Nov 05, 2026, 09:06 PM UTC
L
Halozyme Therapeutics 3Q Rev $493M >HALO
Halozyme Therapeutics 3Q Rev $493M >HALO
EQUITY | Nov 05, 2026, 09:05 PM UTC
L
Halozyme Therapeutics 3Q Net $247M >HALO
Halozyme Therapeutics 3Q Net $247M >HALO
EQUITY | Nov 05, 2026, 09:05 PM UTC
L
Halozyme Therapeutics 3Q EPS $2.01 >HALO
Halozyme Therapeutics 3Q EPS $2.01 >HALO
EARNINGS | Nov 05, 2026, 09:05 PM UTC
H
Halozyme wins Dutch court order to halt Merck Keytruda in eight markets
Halozyme said a Dutch patent court ordered Merck to halt manufacture and sale of injectable Keytruda in eight European markets.
REGULATION | Oct 07, 2026, 06:28 PM UTC
H
Halozyme granted injunction blocking Merck Keytruda formulation in Europe
Halozyme Therapeutics received a court order preventing Merck from manufacturing and distributing a Keytruda formulation in several European markets, following a Hague ruling on patent infringement.
REGULATION | Oct 07, 2026, 03:35 PM UTC
H
Halozyme court order blocks Merck Keytruda in eight European markets
A Dutch patent court ruled for Halozyme, ordering Merck to halt manufacture and sale of injectable Keytruda in eight European markets.
REGULATION | Oct 07, 2026, 01:27 PM UTC
M
Halozyme wins injunction halting Merck’s Keytruda SC manufacture and sale in multiple European markets
Halozyme (HALO) won an injunction stopping the manufacture and sale of Merck’s Keytruda SC in multiple European markets.
REGULATION | Oct 07, 2026, 12:31 PM UTC
M
Halozyme raises $1.5B via 1.50% convertible notes
Halozyme Therapeutics completed a $1.5 billion offering of 1.50% Convertible Senior Notes due 2033, receiving about $1.471 billion in net proceeds. The notes are convertible at an initial price of about $139.84 per share
EQUITY | Sep 22, 2026, 08:43 PM UTC
M
Halozyme prices $1.3B convertible notes due 2033
Halozyme priced $1.3 billion of 1.50% convertible senior notes due 2033 and granted a 13-day option to sell up to $200 million more.
EQUITY | Sep 18, 2026, 12:35 PM UTC
M
Halozyme prices upsized $1.3B 1.50% converts due 2033
Halozyme priced $1.3B of 1.50% convertible senior notes due 2033, upsized from $1.05B. The initial conversion price was $139.84, with capped calls to $208.39. Net proceeds were about $1.275B.
EQUITY | Sep 18, 2026, 03:21 AM UTC
L
HALO - Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
HALO - Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
NEWS | Sep 18, 2026, 03:20 AM UTC
L
HALO - Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
HALO - Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
NEWS | Sep 16, 2026, 08:33 PM UTC
M
Halozyme announces proposed $1.05B convertible notes due 2033
Halozyme Therapeutics said it intends to offer $1.05 billion of convertible senior notes due 2033, subject to market conditions and other factors.
EQUITY | Sep 16, 2026, 08:31 PM UTC
H
HALO: Record revenue, robust pipeline, and new platforms position for sustained royalty growth
Expansion into China and rapid AI adoption are driving operational gains and new partnerships. Record Q2 revenue and a diversified royalty base support strong long-term guidance, while new platforms like Hypercon and Sur
EARNINGS | Sep 15, 2026, 12:44 PM UTC
L
HALO: Record revenues and expanding subQ pipeline drive strong growth and future royalty streams
Record revenue growth driven by ENHANZE and new subcutaneous launches, with expanding pipeline and five new deals supporting future royalties. SubQ delivery is now a commercial mandate, and HyperCon technology is advanci
EQUITY | Sep 09, 2026, 09:23 PM UTC
L
HALO: Subcutaneous delivery platforms drive record growth, new deals, and expanding royalty streams
Record revenue growth is driven by expanding subcutaneous drug delivery platforms, with multiple new deals and launches across ENHANZE and HyperCon. The company is diversifying royalty streams, investing in manufacturing
EQUITY | Sep 09, 2026, 08:46 PM UTC
L
HC Wainwright maintains Halozyme price target at $115/share
HC Wainwright & Co. maintained its price target for Halozyme Therapeutics at $115.00 per share, according to Benzinga ratings action coverage.
EQUITY | Sep 02, 2026, 05:33 PM UTC
L
HALO - Halozyme to Participate at Upcoming Investor Conferences
HALO - Halozyme to Participate at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:30 PM UTC
M
Halo Minerals reports HY before-tax loss of £2.90 million
Halo Minerals reported a HY before-tax loss of £2.90 million.
EQUITY | Aug 28, 2026, 06:20 AM UTC
L
REG - Halo Minerals PLC - Interim Results and Operational Update
REG - Halo Minerals PLC - Interim Results and Operational Update
EQUITY | Aug 28, 2026, 06:00 AM UTC
L
Halozyme appoints Dannielle Appelhans to board
Halozyme (HALO) appoints Dannielle Appelhans to its Board of Directors, according to a TradeXchange Newsdesk update.
REGULATION | Aug 18, 2026, 08:01 PM UTC
L
Crinetics, Alamar, Halozyme Report Earnings
Crinetics, Alamar, and Halozyme report better-than-expected Q2 financial results
EARNINGS | Aug 12, 2026, 12:58 PM UTC
H
Natera, Doximity, PubMatic, Airbnb And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Friday. Shares of Natera Inc (NASDAQ: NTRA ) rose sharply after the company reported better-than-expected quarterly financial results and raised its
EARNINGS | Aug 07, 2026, 07:35 PM UTC
H
JS&P 500 Hits Record As Jobs Shock Sinks Rate-Hike Bets: Stock Market Today
The S&P 500 cleared 7,755 and Wall Street is on course for its best week since April. The rally comes on the heels of a contraction in July payrolls. The U.S. economy unexpectedly shed 23,000 jobs in July against forecas
EARNINGS | Aug 07, 2026, 05:27 PM UTC
L
Halozyme Therapeutics Raises FY2026 Adj EPS Guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 Est; Raises FY2026 Sales Guidance from $1.710B
Halozyme Therapeutics (NASDAQ: HALO ) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 vs $8.14 analyst estimate. Raises FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.835 billion-$1.910 bill
EARNINGS | Aug 06, 2026, 08:03 PM UTC
L
HALO - HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
HALO - HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
EARNINGS | Aug 06, 2026, 08:01 PM UTC
L
INCY HALO Halozyme announces global collaboration and license agreement with Incyte to support the development of subcutaneous formulations
INCY HALO Halozyme announces global collaboration and license agreement with Incyte to support the development of subcutaneous formulations of inca033989 using its enhanze® technology Halozyme Therapeutics - to receive u
EQUITY | Jul 20, 2026, 12:03 PM UTC